Pheochromocytoma: pitfalls in the biochemical evaluation

References

• Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992;147(1):1-10
   PubMedGoogle Scholar
• Grossman A, Pacak K, Sawka A, et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann NY Acad Sci 2006;1073:332-47
   PubMed Web of Science ®Google Scholar
• Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999;141(6):619-24
   PubMed Web of Science ®Google Scholar
• Clifton-Bligh R. Diagnosis of silent pheochromocytoma and paraganglioma. Expert Rev Endocrinol Metab 2013;8:47
   PubMedGoogle Scholar
• Platts JK, Drew PJ, Harvey JN. Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians Lond 1995;29(4):299-306
   PubMedGoogle Scholar
• Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg 2000;179(3):212-15
   PubMed Web of Science ®Google Scholar
• McNeil AR, Blok BH, Koelmeyer TD, et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 2000;30(6):648-52
   PubMedGoogle Scholar
• Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes 2010;118(9):577-85
   PubMedGoogle Scholar
• Crout JR, Sjoerdsma A. Catecholamines in the localization of pheochromocytoma. Circulation 1960;516-25
   PubMedGoogle Scholar
• Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2001;2(3):297-311
   PubMedGoogle Scholar
• Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005;90(4):2068-75
   PubMedGoogle Scholar
• Eisenhofer G, Aneman A, Hooper D, et al. Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 1996;66(4):1565-73
   PubMedGoogle Scholar
• Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153(3):586-600
   PubMedGoogle Scholar
• Hoffman BB, Lefkowitz RJ. Alpha-adrenergic receptor subtypes. N Engl J Med 1980;302(25):1390-6
   PubMedGoogle Scholar
• Arch JR. The beta 3-adrenergic system and beta 3-adrenergic agonists. Rev Endocr Metab Disord 2001;2(4):385-93
   PubMedGoogle Scholar
• Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011;63(1):182-217
   PubMed Web of Science ®Google Scholar
• Pacak K. Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul 2011;45(2):65-90
   PubMedGoogle Scholar
• Pacak K, Keiser H, Eisenhofer G. Pheochromocytoma. In: Groot L, Jameson J, editors. Textbook of endocrinology. De Elsevier Saunders; Philadelphia, PA, USA: 2005. p. 2501
   Google Scholar
• Proye C, Fossati P, Fontaine P, et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 1986;100(6):1154-62
   PubMedGoogle Scholar
• Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287(11):1427-34
   PubMed Web of Science ®Google Scholar
• Perry CG, Sawka AM, Singh R, et al. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 2007;66(5):703-8
   PubMedGoogle Scholar
• Kannan S, Remer EM, Hamrahian AH. Evaluation of patients with adrenal incidentalomas. Curr Opin Endocrinol Diabetes Obes 2013;20(3):161-9
   PubMedGoogle Scholar
• Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab 2011;96(7):2004-15
   PubMedGoogle Scholar
• Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010;39(6):775-83
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88(6):2656-66
   PubMed Web of Science ®Google Scholar
• Eisenhofer G. Editorial: biochemical diagnosis of pheochromocytoma--is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 2003;88(2):550-2
   PubMedGoogle Scholar
• Eisenhofer G, Siegert G, Kotzerke J, et al. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008;40(5):329-37
   PubMedGoogle Scholar
• Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003;88(2):553-8
   PubMed Web of Science ®Google Scholar
• Unger N, Hinrichs J, Deutschbein T, et al. Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. Exp Clin Endocrinol Diabetes 2012;120(8):494-500
   PubMedGoogle Scholar
• Algeciras-Schimnich A, Preissner CM, Young WF Jr, et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008;93(1):91-5
   PubMed Web of Science ®Google Scholar
• Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994;78(5):1139-44
   PubMedGoogle Scholar
• Eisenhofer G, Lattke P, Herberg M, et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem 2013;50(Pt 1):62-9
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thabane L, Gafni A, et al. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age? BMC Endocr Disord 2005;5(1):1
   PubMedGoogle Scholar
• Lenders JW, Willemsen JJ, Eisenhofer G, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem 2007;53(2):352-4
   PubMed Web of Science ®Google Scholar
• Deutschbein T, Unger N, Jaeger A, et al. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clin Endocrinol (Oxf) 2010;73(2):153-60
   PubMedGoogle Scholar
• Därr R, Pamporaki C, Peitzsch M, et al. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) 2013. [Epub ahead of print]
   Google Scholar
• Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 1995;80(10):3009-17
   PubMedGoogle Scholar
• Bracken RM, Linnane DM, Brooks S. Plasma catecholamine and nephrine responses to brief intermittent maximal intensity exercise. Amino Acids 2009;36(2):209-17
   PubMedGoogle Scholar
• Raber W, Raffesberg W, Waldhausl W, et al. Exercise induces excessive normetanephrine responses in hypertensive diabetic patients. Eur J Clin Invest 2003;33(6):480-7
   PubMedGoogle Scholar
• de Jong WH, Eisenhofer G, Post WJ, et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009;94(8):2841-9
   PubMed Web of Science ®Google Scholar
• de Jong WH, Post WJ, Kerstens MN, et al. Elevated urinary free and deconjugated catecholamines after consumption of a catecholamine-rich diet. J Clin Endocrinol Metab 2010;95(6):2851-5
   PubMedGoogle Scholar
• Kerstens MN, Kema IP, Dullaart RP. Plasma normetanephrine concentrations are affected by dietary sodium intake. Clin Chim Acta 2012;413(19-20):1716-17
   PubMedGoogle Scholar
• Masuo K, Ogihara T, Kumahara Y, et al. Plasma norepinephrine and dietary sodium intake in normal subjects and patients with essential hypertension. Hypertension 1983;5(5):767-71
   PubMedGoogle Scholar
• Grassi G, Seravalle G, Calhoun DA, et al. Cigarette smoking and the adrenergic nervous system. Clin Exp Hypertens A 1992;14(1-2):251-60
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Huysmans F, Pacak K, et al. Plasma metanephrines in renal failure. Kidney Int 2005;67(2):668-77
   PubMedGoogle Scholar
• Goldstein DS, Lake CR. Plasma norepinephrine and epinephrine levels in essential hypertension. Fed Proc 1984;43(1):57-61
   PubMedGoogle Scholar
• Kobayashi K, Kolloch R, Dequattro V, Miano L. Increased plasma and urinary normetanephrine in young patients with primary hypertension. Clin Sci (Lond) 1979;57(Suppl 5):173s-6s
   PubMedGoogle Scholar
• Eisenhofer G, Friberg P, Pacak K, et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Lond) 1995;88(5):533-42
   PubMedGoogle Scholar
• Lehmann M, Keul J. Urinary excretion of free noradrenaline and adrenaline related to age, sex and hypertension in 265 individuals. Eur J Appl Physiol Occup Physiol 1986;55(1):14-18
   PubMedGoogle Scholar
• Eisenhofer G, Whitley RJ, Rosano TG. Catecholamines and serotonin. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. Elsevier; USA: 2012. p. 851
   Google Scholar
• Bravo EL, Tarazi RC, Fouad FM, et al. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981;305(11):623-6
   PubMed Web of Science ®Google Scholar
• Bravo EL. Pheochromocytoma. Current concepts in diagnosis, localization, and management. Prim Care 1983;10(1):75-86
   PubMedGoogle Scholar
• Elliott WJ, Murphy MB. Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels. Am J Med 1988;84(3 Pt 1):419-24
   PubMedGoogle Scholar
• Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992;152(6):1193-7
   PubMedGoogle Scholar
• Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366(9486):665-75
   PubMed Web of Science ®Google Scholar
• Elmasry A, Lindberg E, Hedner J, et al. Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. Eur Respir J 2002;19(3):511-17
   PubMedGoogle Scholar
• Hoy LJ, Emery M, Wedzicha JA, et al. Obstructive sleep apnea presenting as pseudopheochromocytoma: a case report. J Clin Endocrinol Metab 2004;89(5):2033-8
   PubMedGoogle Scholar
• Morton AP. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust 2005;183(5):279; author reply 279
   PubMedGoogle Scholar
• Leow MK, Loh KC, Kiat Kwek T, Ng PY. Catecholamine and metanephrine excess in intracerebral haemorrhage: revisiting an obscure yet common “pseudophaeochromocytoma”. J Clin Pathol 2007;60(5):583-4
   PubMedGoogle Scholar
• Nicholls KM, Shapiro MD, Van Putten VJ, et al. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res 1985;56(3):457-61
   PubMedGoogle Scholar
• Zaloga GP, Chernow B, Fletcher JR, et al. Increased circulating plasma norepinephrine concentrations in noncardiac causes of pulmonary hypertension. Crit Care Med 1984;12(2):85-9
   PubMedGoogle Scholar
• Harding JL, Yeh MW, Robinson BG, et al. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust 2005;182(12):637-40
   PubMedGoogle Scholar
• Fann WE, Davis JM, Janowsky DS, et al. Effect of antidepressant and antimanic drugs on amine uptake in man. J Nerv Ment Dis 1974;158(5):361-8
   PubMedGoogle Scholar
• Neary NM, King KS, Pacak K. Drugs and pheochromocytoma--don't be fooled by every elevated metanephrine. N Engl J Med 2011;364(23):2268-70
   PubMed Web of Science ®Google Scholar
• Doogue M, Soule S, Hunt P. Another cause of ‘pseudophaeochromocytoma’--quetiapine associated with a false positive normetanephrine result. Clin Endocrinol (Oxf) 2007;67(3):472-3
   PubMedGoogle Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39(1):32-41
   PubMed Web of Science ®Google Scholar
• Mussig K, Haring HU, Schleicher ED. Pseudopheochromocytoma in Parkinson's disease. Eur J Intern Med 2008;19(2):151-2
   PubMedGoogle Scholar
• Tischendorf JJ, Karges W, Schofl C. Catecholamine excess in a patient with restless legs syndrome treated with levodopa and benserazide. Endocr Pract 2009;15(3):275-6
   PubMedGoogle Scholar
• Eisenhofer G, Brown S, Peitzsch M, et al. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem 2014;51(Pt 1):38-46
   PubMedGoogle Scholar
• Goldberg WM. False-positive test for catecholamines. Can Med Assoc J 1964;91(25):1326
   PubMedGoogle Scholar
• Langer SZ, Arbilla S. Presynaptic receptors and modulation of the release of noradrenaline, dopamine and GABA. Postgrad Med J 1981;57(Suppl 1):18-29
   PubMedGoogle Scholar
• Kuchel O, Buu NT, Hamet P, Larochelle P. Effect of metoclopramide on plasma catecholamine release in essential hypertension. Clin Pharmacol Ther 1985;37(4):372-5
   PubMedGoogle Scholar
• Crawford GA, Gallery ED, Gyory AZ. Removal of interference by antihypertensive drugs in the spectrophotometric assay of metanephrines. Clin Chim Acta 1987;169(1):117-19
   PubMedGoogle Scholar
• Bouloux PM, Perrett D. Interference of labetalol metabolites in the determination of plasma catecholamines by HPLC with electrochemical detection. Clin Chim Acta 1985;150(2):111-17
   PubMedGoogle Scholar
• Manickum T. Interferences by anti-TB drugs in a validated HPLC assay for urinary catecholamines and their successful removal. J Chromatogr B Analyt Technol Biomed Life Sci 2008;873(1):124-8
   PubMedGoogle Scholar
• Goldstein DS, Stull R, Markey SP, et al. Dihydrocaffeic acid: a common contaminant in the liquid chromatographic-electrochemical measurement of plasma catecholamines in man. J Chromatogr 1984;311(1):148-53
   PubMedGoogle Scholar
• Lenders JW, Eisenhofer G, Armando I, et al. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 1993;39(1):97-103
   PubMedGoogle Scholar
• van Laarhoven HW, Willemsen JJ, Ross HA, et al. Pitfall in HPLC assay for urinary metanephrines: an unusual type of interference caused by methenamine intake. Clin Chem 2004;50(6):1097-9
   PubMedGoogle Scholar
• Ito T, Imai T, Kikumori T, et al. Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today 2006;36(11):961-5
   PubMedGoogle Scholar
• Cook FJ, Chandler DW, Snyder DK. Effect of buspirone on urinary catecholamine assays. N Engl J Med 1995;332(6):401
   PubMedGoogle Scholar
• Sheps SG. Sotalol and pheochromocytoma results. Am J Hypertens 1994;7(2):213
   PubMedGoogle Scholar
• Sohn SY, Park HD, Lee SY, et al. Different diagnostic cut-off values of urinary fractionated metanephrines according to sex for the diagnosis of pheochromocytoma in Korean subjects. Endocr J 2012;59(9):831-8
   PubMedGoogle Scholar
• Cameron OG, Curtis GC, Zelnik T, et al. Circadian fluctuation of plasma epinephrine in supine humans. Psychoneuroendocrinology 1987;12(1):41-51
   PubMedGoogle Scholar
• Hoizey G, Lukas-Croisier C, Frances C, et al. Study of diurnal fluctuations of plasma methoxyamines in healthy volunteers. Clin Endocrinol (Oxf) 2002;56(1):119-22
   PubMedGoogle Scholar
• Osinga TE, van den Eijnden MH, Kema IP, et al. Unilateral and bilateral adrenalectomy for pheochromocytoma requires adjustment of urinary and plasma metanephrine reference ranges. J Clin Endocrinol Metab 2013;98(3):1076-83
   PubMedGoogle Scholar
• Spilker B, Watson BS, Woods JW. Drug interference with measurement of metanephrines in urine. Ann Clin Lab Sci 1983;13(1):16-19
   PubMedGoogle Scholar